Back to News
Market Impact: 0.15
Takeda's TAK-881 Cuts Infusion Time By 42.6% In Phase 3 PID Study
Source: Nasdaq
Healthcare & Biotech
Takeda presented detailed Phase 2/3 IgGNITE study results for investigational subcutaneous therapy TAK-881 in patients with Primary Immunodeficiency; the provided article text is truncated before reporting any results. No efficacy, safety, or market-response figures are available in the excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
TAK0.00
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
- Why is Olympus stock plunging today?